Clinical Trial: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Atopic Dermatitis

U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863961) titled 'A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Atopic Dermatitis' on March 04.

Brief Summary: The purpose of this study is to assess the efficacy and safety of RO7790121 in participants with moderate to severe atopic dermatitis (AD).

Study Start Date: March 14

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis

Intervention: DRUG: RO7790121

RO7790121 will be administered as SC injection.

DRUG: Placebo

Placebo will be administered as SC injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hoffmann-La Roche

Disclaimer: Curated by HT Syndication....